GlobeNewswire

Cavotec’s Nomination Committee ahead of Annual General Meeting 2020

Share

The Nomination Committee of Cavotec SA (“Cavotec”) consists of members appointed by Cavotec’s Board of Directors, in accordance with Cavotec's Internal Regulations. The composition of the members of the Nomination Committee presented below is in line with the recommendations of the Swedish Corporate Governance Code. The main purpose and responsibility of the Nomination Committee is to present proposals for the election and remuneration of the Chairman and the Board of Directors as well as the Auditors to the Annual General Meeting 2020. 

The Board of Directors has decided that the four largest shareholders and the Chairman of Cavotec’s Board of Directors shall be represented in the Nomination Committee. On 31 October 2019, the four largest shareholders recorded in the company’s share register were Bure Equity AB (27.1% of the vote), AP4 (9.8% of the vote), Nomina SA (8.1% of the vote) and Founding Shareholders (Stefan Widegren, Lars Hellman and Peter Brandel with families) (11.9 % of the vote). 

Upon nomination from the major shareholders, the Board of Directors has appointed the following representatives to the Nomination Committee:

  •  Henrik Blomquist, who represents Bure Equity AB
  •  Thomas Ehlin, who represents The Fourth Swedish National Pension Fund (AP4)
  •  Fabio Cannavale, who represents Nomina SA 
  •  Stefan Widegren, who represents the Founding Shareholders 
  •  Patrik Tigerschiöld, Chairman of Cavotec’s Board of Directors 

The above calculation is based on 94,243,200 shares, which represents the total number of ordinary shares in Cavotec.

Cavotec’s Annual General Meeting for the financial year 1 January 2019 – 31 December 2019 will be held on 15 May 2020. In order for the Nomination Committee to be able to evaluate the proposals received with due care, proposals must be submitted by no later than 18 March 2020. The Nomination Committee’s proposals will be presented in the Notice convening the Annual General Meeting 2020 and on the company’s website.

Shareholders in Cavotec should send proposals to the Nomination Committee by email to nomination@cavotec.com.

ENDS

For further details please contact:

Johan Hähnel
Investor Relations Manager
Telephone: +46 70 605 63 34. Email: investor@cavotec.com

This information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on 15 November 2019.

About Cavotec
Cavotec is a leading engineering group that designs and manufactures automated connection and electrification systems for ports, airports and industrial applications worldwide. Cavotec’s innovative technologies ensure safe, efficient and sustainable operationsTo find out more about Cavotec, visit our website at cavotec.com .

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development´s portfolio company Umecrine Cognition completes enrollment to phase 2a study in liver cirrhosis and hepatic encephalopaty13.12.2019 08:00:00 CETPress release

STOCKHOLM, SWEDEN – December 13, 2019. Karolinska Development´s portfolio company Umecrine Cognition announces today that the enrollment has been completed in its Phase 2a study designed to assess the safety, pharmacokinetics and potential benefit of golexanolone in patients with liver cirrhosis and hepatic encephalopathy. Umecrine Cognition is developing golexanolone (GR3027), a novel GABAA receptor modulating steroid antagonist with a potential to improve brain function in a wide range of cognitive disorders. Golexanolone is presently in clinical development for hepatic encephalopathy (HE), a serious neuropsychiatric and neurocognitive complication in acute and chronic liver disease (including cirrhosis). At present there are no treatments available that directly target the brain abnormalities believed to be responsible for HE. The study UCAB-CT-02 is a prospective, double-blind, randomized, placebo-controlled multi-center phase 1b/2a protocol in four parts enrolling healthy adults a

Ahold Delhaize share buyback update13.12.2019 08:00:00 CETPress release

Zaandam, the Netherlands, December 13, 2019 – Ahold Delhaize has repurchased 584,327 of Ahold Delhaize common shares in the period from December 9, 2019 up to and including December 11, 2019. The shares were repurchased at an average price of €23.04 per share for a total consideration of €13.5 million. These repurchases were made as part of the €1 billion share buyback program announced on November 13, 2018. The total number of shares repurchased under this program during the financial year 2019 is 45,621,384 common shares for a total consideration of €1 billion. Ahold Delhaize confirms the successful completion of the program on December 11, 2019. The number of outstanding common shares as of this date was 1,087,955,597. Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/ This press release is issued in connection with the disclosure and reporting obligati

Karolinska Developments portföljbolag Umecrine Cognition har slutfört inkludering i fas 2a-studie vid levercirros och hepatisk encefalopati13.12.2019 08:00:00 CETPressemelding

STOCKHOLM, SVERIGE 13 december 2019. Karolinska Developments portföljbolag Umecrine Cognition meddelar idag att de har slutfört inkluderingen i den kliniska fas 2a-studie vars syfte är att utvärdera säkerhet, farmakokinetik och potentiell nytta av golexanolon som behandling för patienter med levercirros och leverencefalopati. Umecrine Cognition utvecklar golexanolon (GR3027), en innovativ GABAA-receptormodulerande steroidantagonist med potential att förbättra hjärnfunktionen vid en rad olika kognitiva tillstånd. Golexanolon är för närvarande i klinisk utveckling för behandling vid hepatisk encefalopati (HE), även kallat leverkoma, en neurologisk och psykiatrisk komplikation vid akut eller kronisk leverskada inklusive cirros (skrumplever). Det finns ännu ingen behandling tillgänglig som riktas mot de hjärnförändringar som tros vara orsaken till HE. Studien UCAB-CT-02 är en prospektiv, multicenter, dubbelblind, randomiserad, placebokontrollerad fas 1b/2a-studie i fyra delar som inkludera

Granted NOK 37.6 million to deliver hydrogen to ferries and cruise ships in the Geirangerfjord13.12.2019 07:45:00 CETPress release

The Hellesylt Hydrogen Hub, a consortium of leading players in the hydrogen field, including Hexagon, has been awarded NOK 37.6 million under the PILOT-E funding scheme for the development of a hydrogen production facility that can deliver hydrogen to ferries and cruise ships in the Geirangerfjord, as well as to other mobility applications. The ambition is to achieve zero-emission operations in the Geirangerfjord, one of two World Heritage Fjords in Norway, by producing green hydrogen locally. See attached press release by Flakk Gruppen for more information. For more information: Hiva Ghiri, VP Investor Relations, Hexagon Composites Telephone: +47 958 66 790 | hiva.ghiri@hexagongroup.com Solveig D Saether, Communication Manager, Hexagon Composites ASA Telephone: +47 906 34 977 | solveig.saether@hexagongroup.com About Hexagon Composites Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy

SBM Offshore divests minority interest in FPSO Sepetiba project13.12.2019 07:30:00 CETPress release

December 13, 2019 Following the announcement on December 11, 2019, with respect to the contract signature for FPSO Sepetiba, SBM Offshore is pleased to announce that it has entered into a shareholder agreement with its long standing business partners Mitsubishi Corporation (MC) and Nippon Yusen Kabushiki Kaisha (NYK) regarding the divestment of a 35.5% interest in the special purpose companies related to the lease and operation of FPSO Sepetiba. MC acquired 20% and NYK acquired 15.5% ownership interest in the companies. SBM Offshore is operator and majority shareholder with the remaining 64.5% ownership interest. FPSO Sepetiba is currently under construction. The FPSO will be deployed at the Mero field in the Santos Basin offshore Brazil, 180 kilometers offshore Rio de Janeiro, under a 22.5 years lease and operate contract with Petróleo Brasileiro S.A. (Petrobras). Delivery of the FPSO is expected in 2022. The financial effects from this divestment were anticipated in SBM Offshore’s fu

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma13.12.2019 07:00:00 CETPress release

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety profile observed in IMspire150 was consistent with the known safety profiles of the individual medicines. Results from the study will be presented at an upcoming medical meeting and discussed with health authorities, including the U.S. Food and Drug Administration